

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

PCT / SE 2004 / 001049

REC'D 14 JUL 2004

WIPO PCT

Intyg
Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.




(71) Sökande Affibody AB, Bromma SE
Applicant (s)

(21) Patentansökningsnummer 0400275-4
Patent application number

(86) Ingivningsdatum 2004-02-09
Date of filing

Stockholm, 2004-07-07

För Patent- och registreringsverket
For the Patent- and Registration Office


Gunilla Larsson

Avgift
Fee

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

AWAPATENT ABKontor/Handläggare
Stockholm/Niklas Mattsson/NMN**Affibody AB**

Ansökningsnr

Vår referens
SE-21012330

Ink. t. Patent- och reg.verket

1

2004-02-09

NEW POLYPEPTIDE

Huvudfaxen Kassar

Field of the invention

The present invention is related to a new polypeptide, which binds to Human Epidermal Growth Factor Receptor 2 (in the following referred to as HER2). The polypeptide is related to a domain of staphylococcal protein A (SPA) in that the sequence of the polypeptide corresponds to the sequence of the SPA domain having at least one substitution mutation. The present invention also relates to use of such a HER2 binding polypeptide as a medicament, more particularly use thereof for the preparation of a medicament for treatment of forms of cancer characterized by overexpression of HER2.

Background

15

Affibody® molecules

Molecules related to protein Z, derived from domain B of staphylococcal protein A (SPA) (Nilsson B et al (1987) Protein Engineering 1, 107-133), have been selected from a library of randomized such molecules using different interaction targets (see e g WO95/19374; WO00/63243; Nord K et al (1995) Prot Eng 8:601-608; Nord K et al (1997) Nature Biotechnology 15, 772-777). Different target molecules have been used to select such protein Z derivatives, e g as described in Nord K et al (1997, *supra*). The experiments described in this reference outline principles of the general technology of selecting protein Z derivatives against given targets, rather than being a study directed towards the express objective of obtaining a molecule with high enough affinity for use in a specific therapeutic or biotechnological application.

HER2 and its role in cancer diseases

The HER2 proto-oncogene encodes the production of a 185 kD cell surface receptor protein known as the HER2 protein or receptor (Hynes NE et al (1994) Biochim Biophys Acta 1198:165-184). This gene is also sometimes referred to as neu, HER2/neu or c-erbB-2. Neu was first discovered in rats that had been treated with ethylnitrosourea, and exhibited mutation of this gene (Shih C et al (1981) Nature 290:261-264). The mutated version of neu results in the production of a constitutively active form of the receptor, and constitutes a potent oncogene that can transform cells at low copy number (Hynes NE et al, supra).

Normal cells express a small amount of HER2 protein on their plasma membranes in a tissue-specific pattern. No known ligand to HER2 has been elucidated; however, HER2 has been shown to form heterodimers with HER1 (the epidermal growth factor receptor, EGFR), HER3 and HER4 in complex with the ligands for these receptors. Such formation of heterodimer leads to the activated HER2 receptor transmitting growth signals from outside the cell to the nucleus, thus controlling aspects of normal cell growth and division (Sundaresan S et al (1999) Curr Oncol Rep 1:16-22).

In tumor cells, errors in the DNA replication system may result in the existence of multiple copies of a gene on a single chromosome, which is a phenomenon known as gene amplification. Amplification of the HER2 gene leads to an increased transcription of this gene. This elevates HER2 mRNA levels and increases the concomitant synthesis of HER2 protein, which results in HER2 protein overexpression on the surface of these tumor cells. This overexpression can result in HER2 protein levels that are 10- to 100-fold greater than those found in the adjacent normal cells. This, in turn, results in increased cell division and a concomitantly higher rate of cell growth. Amplification of the HER2 gene is implicated in transforma-

tion of normal cells to the cancer phenotype (Hynes NE et al, *supra*; Sundaresan S et al, *supra*).

Overexpression of HER2 protein is thought to result in the formation of homodimers of HER2, which in turn results in a constitutively active receptor (Sliwkowski MX et al (1999) *Semin Oncol* 26(4 Suppl 12):60-70). Under these conditions, growth-promoting signals may be continuously transmitted into the cells in the absence of ligands. Consequently, multiple intracellular signal transduction pathways become activated, resulting in unregulated cell growth and, in some instances, oncogenic transformation (Hynes NE et al, *supra*). Thus, the signal transduction mechanisms mediated by growth factor receptors are important targets for inhibiting cell replication and tumor growth.

Breast cancer is the most common malignancy among women in the United States, with 192200 new cases projected to have occurred in 2001 (Greenlee R et al (2001) *CA Cancer J Clin* 51:15-36). In approximately 25 % of all breast cancer patients, there is an overexpression of the HER2 gene due to amplification thereof (Slamon DJ et al (1989) *Science* 244:707-712). This overexpression of HER2 protein correlates with several negative prognostic variables, including estrogen receptor-negative status, high S-phase fraction, positive nodal status, mutated p53, and high nuclear grade (Sjogren S et al (1998) *J Clin Oncol* 16(2):462-469). According to Slamon et al (*supra*), the amplification of the HER2 gene was found to correlate strongly with shortened disease-free survival and shortened overall survival of node-positive patients.

For these reasons, it has been, and is still, an important goal to further pursue investigations into the role of HER2 in the pathogenesis and treatment of breast cancer. The identification of molecules that interact with HER2 forms one part of this effort.

Preclinical *in vitro* studies have examined whether inhibition of HER2 activity could affect tumor cell

2004-04-09

Huvudfaxen Kassar

4

growth. Treatment of SK-BR-3 breast cancer cells overexpressing HER2 protein with 4D5, one of several murine anti-HER2 monoclonal antibodies, did indeed inhibit tumor cell proliferation, compared to treatment with a control monoclonal antibody. Administration of 4D5 to mice bearing human breast and ovarian cancers (xenografts) that overexpress HER2 prolonged their tumor-free survival time. Similar studies demonstrated the growth inhibition by anti-HER2 monoclonal antibodies in human gastric cancer xenografts in mice (Pietras RJ et al (1994) Oncogene 9:1829-1838).

Among the approaches to inhibiting the HER2 protein abundantly present on tumor cell surfaces with an antibody, one therapy has become commercially available during recent years. Thus, the monoclonal antibody 4D5, or trastuzumab, is marketed for this purpose by F Hoffman-La Roche and Genentech under the trade name of Herceptin®.

Notwithstanding the obvious advantages shown by antibody therapy against cancers characterized by overexpression of HER2 protein, the fact remains that a variety of factors have the potential of reducing antibody efficacy (see e g Reilly RM et al (1995) Clin Pharmacokinet 28:126-142). These include the following: (1) limited penetration of the antibody into a large solid tumor or into vital regions such as the brain; (2) reduced extravasation of antibodies into target sites owing to decreased vascular permeability; (3) cross-reactivity and nonspecific binding of antibody to normal tissues, reducing the targeting effect; (4) heterogeneous tumor uptake resulting in untreated zones; (5) increased metabolism of injected antibodies, reducing therapeutic effects; and (6) rapid formation of HAMA and human antihuman antibodies, inactivating the therapeutic antibody.

In addition, toxic effects have been a major obstacle in the development of therapeutic antibodies for cancer (Carter P (2001) Nat Rev Cancer 1:118-129; Goldenberg DM (2002) J Nucl Med 43:693-713; Reichert JM (2002) Curr

Opin Mol Ther 4:110-118). Cross-reactivity with healthy tissues can cause substantial side effects for unconjugated (naked) antibodies, which side effects may be enhanced upon conjugation of the antibodies with toxins or radioisotopes. Immune-mediated complications include dyspnea from pulmonary toxic effects, occasional central and peripheral nervous system complications, and decreased liver and renal function. On occasion, unexpected toxic complications can be seen, such as the cardiotoxic effects associated with the HER-2 targeting antibody trastuzumab (Herceptin®) (Schneider JW et al (2002) Semin Oncol 29(3 suppl 11):22-28). Radioimmunotherapy with isotope-conjugated antibodies also can cause bone marrow suppression.

Despite the recent clinical and commercial success of the currently used anticancer antibodies, a substantial number of important questions thus remain concerning the future of this therapeutic strategy. As a consequence, the continued provision of agents with a comparable affinity for HER2 remains a matter of substantial interest within the field, as well as the provision of uses of such molecules in the treatment of disease.

Disclosure of the invention

It is an object of the present invention to satisfy this interest through the provision of a polypeptide that is characterized by specific binding to HER2.

A related object of the invention is an HER2 binding polypeptide which exhibits little or no non-specific binding.

It is another object of the invention to provide an HER2 binding polypeptide that can readily be used as a moiety in a fusion polypeptide.

Another object is the provision of an HER2 binding polypeptide, which solve one or more of the known problems experienced with existing antibody reagents.

2007-02-09

Huvudföreläsaren Kansson

6

A further object of the invention is to provide an HER2 binding polypeptide, which is amenable to use in therapeutic applications.

5 A related object is to find new forms for the treatment, inhibition and/or targeting in the clinical setting of cancer diseases characterized by an overexpression of HER2 protein.

10 It is also an object to provide a molecule which can be used as a reagent for the detection of HER2 at a low detection limit.

These and other objects are met by the different aspects of the invention as claimed in the appended claims. Thus, in a first aspect, the invention provides a polypeptide, which has a binding affinity for HER2 and which
15 is related to a domain of staphylococcal protein A (SPA) in that the sequence of the polypeptide corresponds to the sequence of the SPA domain having from 1 to about 20 substitution mutations.

20 In an embodiment of the polypeptide according to this aspect of the invention, the affinity thereof for HER2 is such that the K_D value of the interaction is at most 1×10^{-6} M. In another embodiment, the affinity of the polypeptide for HER2 is such that the K_D value of the interaction is at most 1×10^{-7} M.

25 In another embodiment, the polypeptide according to the invention binds specifically to the extracellular domain, ECD, of the HER2 protein.

In accordance herewith, the present inventors have found that it is possible to obtain a high-affinity HER2
30 binding polypeptide through substitution mutagenesis of a domain from SPA, and that such a polypeptide is able to interact with HER2. The inventive polypeptide finds application as an alternative to antibodies against HER2 in diverse applications. As non-limiting examples, it will
35 be useful in the treatment of cancers characterized by HER2 overexpression, in inhibiting cell signaling by binding to the HER2 on a cell surface, in the diagnosis

of cancer both *in vivo* and *in vitro*, in targeting of agents to cells overexpressing HER2, in histochemical methods for the detection of HER2, in methods of separation and other applications. The polypeptide according to 5 the invention may prove useful in any method which relies on affinity for HER2 of a reagent. Thus, the polypeptide may be used as a detection reagent, a capture reagent or a separation reagent in such methods, but also as a therapeutic agent in its own right or as a means for tar- 10 geting other therapeutic agents to the HER2 protein. Methods that employ the polypeptide according to the invention *in vitro* may be performed in different formats, such as in microtiter plates, in protein arrays, on bio-sensor surfaces, on tissue sections, and so on. Different 15 modifications of, and/or additions to, the polypeptide according to the invention may be performed in order to tailor the polypeptide to the specific use intended, without departing from the scope of the present invention. Such modifications and additions are described in 20 more detail below, and may comprise additional amino acids comprised in the same polypeptide chain, or labels and/or therapeutic agents that are chemically conjugated or otherwise bound to the polypeptide according to the invention. Furthermore, the invention also encompasses 25 fragments of the polypeptide that retain the capability of binding to HER2.

"Binding affinity for HER2" refers to a property of a polypeptide which may be tested e g by the use of surface plasmon resonance technology, such as in a Biacore® 30 instrument. HER2 binding affinity may be tested in an experiment wherein HER2 is immobilized on a sensor chip of the instrument, and a sample containing the polypeptide to be tested is passed over the chip. Alternatively, the polypeptide to be tested is immobilized on a sensor chip 35 of the instrument, and a sample containing HER2 is passed over the chip. The skilled person may then interpret the sensorgrams obtained to establish at least a qualitative

measure of the polypeptide's binding affinity for HER2. If a quantitative measure is sought, e g with the purpose to establish a certain K_D value for the interaction, it is again possible to use surface plasmon resonance methods. Binding values may e g be defined in a Biacore® 2000 instrument (Biacore AB). HER2 is immobilized on a sensor chip of the instrument, and samples of the polypeptide whose affinity is to be determined are prepared by serial dilution and injected in random order. K_D values may then be calculated from the results, using e g the 1:1 Langmuir binding model of the BIAevaluation 3.2 software provided by the instrument manufacturer.

As stated above, the sequence of the polypeptide according to the present invention is related to the SPA domain sequence in that from 1 to about 20 amino acid residues of said SPA domain have been substituted for other amino acid residues. However, the substitution mutations introduced should not affect the basic structure of the polypeptide. That is, the overall fold of the C_α backbone of the polypeptide of the invention will be essentially the same as that of the SPA domain to which it is related, e g having the same elements of secondary structure in the same order etc. Thus, polypeptides fall under the definition of having the same fold as the SPA domain if basic structural properties are shared, those properties e g resulting in similar CD spectra. The skilled person is aware of other parameters that are relevant. This requirement of essentially conserving the basic structure of the SPA domain, upon mutation thereof, places restrictions on what positions of the domain may be subject to substitution. When starting from the known structure of the Z protein, for example, it is preferred that amino acid residues located on the surface of the Z protein are substituted, whereas amino acid residues buried within the core of the Z protein "three-helix bundle" should be kept constant in order to preserve the struc-

tural properties of the molecule. The same reasoning applies to other SPA domains, and fragments thereof.

The invention also encompasses polypeptides in which the HER2 binding polypeptide described above is present
5 as an HER2 binding domain, to which additional amino acid residues have been added at either terminal. These additional amino acid residues may play a role in the binding of HER2 by the polypeptide, but may equally well serve other purposes, related for example to one or more of the
10 production, purification, stabilization, coupling or detection of the polypeptide. Such additional amino acid residues may comprise one or more amino acid residues added for purposes of chemical coupling. An example of this is the addition of a cysteine residue at the very
15 first or very last position in the polypeptide chain, i.e. at the N or C terminus. Such additional amino acid residues may also comprise a "tag" for purification or detection of the polypeptide, such as a hexahistidyl (His₆) tag, or a "myc" tag or a "flag" tag for interaction with
20 antibodies specific to the tag. The skilled person is aware of other alternatives.

The "additional amino acid residues" discussed above may also constitute one or more polypeptide domain(s) with any desired function, such as the same binding function as the first, HER2-binding domain, or another binding
25 function, or an enzymatic function, or a fluorescent function, or mixtures thereof.

Thus, the invention encompasses multimers of the polypeptide with affinity for HER2. It may be of interest, e.g. when using the polypeptide according to the invention for treatment of cancer or in a method of purification of HER2, to obtain even stronger binding of HER2 than is possible with one polypeptide according to the invention. In this case, the provision of a multimer,
30 such as a dimer, trimer or tetramer, of the polypeptide may provide the necessary avidity effects. The multimer may consist of a suitable number of polypeptides accord-

ing to the invention. These polypeptide domains according
to the invention, forming monomers in such a multimer,
may all have the same amino acid sequence, but it is
equally possible that they have different amino acid se-
5 quences. The linked polypeptide "units" in a multimer ac-
cording to the invention may be connected by covalent
coupling using known organic chemistry methods, or ex-
pressed as one or more fusion polypeptides in a system
for recombinant expression of polypeptides, or joined in
10 any other fashion, either directly or via a linker, for
example an amino acid linker.

Additionally, "heterogenic" fusion polypeptides, in
which the HER2 binding polypeptide constitutes a first
domain, or first moiety, and the second and further moie-
15 ties have other functions than binding HER2, are also
contemplated and fall within the ambit of the present in-
vention. The second and further moiety/moieties of the
fusion polypeptide may comprise a binding domain with af-
finity for another target molecule than HER2. Such a
20 binding domain may well also be related to an SPA domain
through substitution mutation at from 1 to about 20 posi-
tions thereof. The result is then a fusion polypeptide
having at least one HER2-binding domain and at least one
domain with affinity for said other target molecule, in
25 which both domains are related to an SPA domain. This
makes it possible to create multispecific reagents that
may be used in several biotechnological applications,
such as used as therapeutic agents or as capture, detec-
tion or separation reagents. The preparation of such mul-
30 tispecific multimers of SPA domain related polypeptides,
in which at least one polypeptide domain has affinity for
HER2, may be effected as described above for the multimer
of several HER2 binding "units". In other alternatives,
the second or further moiety or moieties may comprise an
35 unrelated, naturally occurring or recombinant, protein
(or a fragment thereof retaining the binding capability
of the naturally occurring or recombinant protein) having

a binding affinity for a target. An example of such a binding protein, which has an affinity for human serum albumin and may be used as fusion partner with the HER2 binding SPA domain derivative of the invention, is the albumin binding domain of streptococcal protein G (SPG) (Nygren P-Å et al (1988) Mol Recogn 1:69-74). A fusion polypeptide between the HER2 binding SPA domain-related polypeptide and the albumin binding domain of SPG thus falls within the scope of the present invention. When the polypeptide according to the invention is administered to a human subject as a therapeutic agent or as a targeting agent, the fusion thereof to a moiety which binds serum albumin may prove beneficial, in that the half-life in vivo of such a fusion protein may likely prove to be prolonged as compared to the half-life of the SPA domain related HER2 binding moiety in isolation (this principle has been described e g in WO91/01743).

Other possibilities for the creation of fusion polypeptides are also contemplated. Thus, the HER2 binding SPA domain-related polypeptide according to the first aspect of the invention may be covalently coupled to a second or further moiety or moieties, which in addition to, or instead of, target binding exhibit other functions. One example is a fusion between one or more HER2 binding polypeptide(s) and an enzymatically active polypeptide serving as a reporter or effector moiety. Examples of reporter enzymes, which may be coupled to the HER2 binding polypeptide to form a fusion protein, are known to the skilled person and include enzymes such as β -galactosidase, alkaline phosphatase, horseradish peroxidase, carboxypeptidase. Other options for the second and further moiety or moieties of a fusion polypeptide according to the invention include fluorescent polypeptides, such as green fluorescent protein, red fluorescent protein, luciferase and variants thereof.

Other options for the second and further moiety or moieties of a fusion polypeptide according to the inven-

tion include a moiety or moieties for therapeutic applications. In therapeutic applications, other molecules may also be conjugated, covalently or non-covalently, to the inventive polypeptide by other means. Non-limiting examples include enzymes for "ADEPT" (antibody-directed enzyme prodrug therapy) applications using the polypeptide according to the invention for direction of the effector enzyme (e g carboxypeptidase); proteins for recruitment of effector cells and other components of the immune system; cytokines, such as IL-2, IL-12, TNF α , IP-10; procoagulant factors, such as tissue factor, von Willebrand factor; toxins, such as ricin A, *Pseudomonas* exotoxin, calcheamicin, maytansinoid; toxic small molecules, such as auristatin analogs, doxorubicin. Also, the above named additional amino acids (notably hexahistidine tag, cysteine), provided with the aim of conjugating chelators for radioisotopes to the polypeptide sequence, are contemplated, in order to easily incorporate radiating nuclides for diagnosis (e g ^{68}Ga , ^{76}Br , ^{111}In , ^{99}Tc , ^{124}I , ^{125}I) or therapy (e g ^{90}Y , ^{131}I , ^{211}At).

The invention encompasses polypeptides in which the HER2 binding polypeptide described above has been provided with a label group, such as at least one fluorophore, biotin or a radioactive isotope, for example for purposes of detection of the polypeptide.

With regard to the description above of fusion proteins incorporating the HER2 binding polypeptide according to the invention, it is to be noted that the designation of first, second and further moieties is made for clarity reasons to distinguish between the HER2 binding moiety or moieties on the one hand, and moieties exhibiting other functions on the other hand. These designations are not intended to refer to the actual order of the different domains in the polypeptide chain of the fusion protein. Thus, for example, said first moiety may without restriction appear at the N-terminal end, in the middle, or at the C-terminal end of the fusion protein.

An example of an SPA domain for use as a starting point for the creation of a polypeptide according to the invention is protein Z, derived from domain B of staphylococcal protein A. As pointed out in the Background section, this protein has previously been used as a scaffold structure for the creation of molecules, denoted Affibody® molecules, capable of binding to a variety of targets. The 58 amino acid sequence of unmodified protein Z, denoted Z_{wt}, is set out in SEQ ID NO:1 and illustrated in Figure 1.

In an embodiment of the polypeptide according to the invention, it is related to a domain of SPA in that the sequence of the polypeptide corresponds to the sequence of the SPA domain having from 4 to about 20 substitution mutations. Other embodiments may have from 1 to about 13 substitution mutations, or from 4 to about 13 substitution mutations.

In a more specific embodiment of the polypeptide according to the invention, its sequence corresponds to the sequence set forth in SEQ ID NO:1 having from 1 to about 20 substitution mutations, such as from 4 to about 20, from 1 to about 13 or from 4 to about 13 substitution mutations.

The polypeptide according to the invention may in some embodiments correspond to the sequence set forth in SEQ ID NO:1, which sequence comprises substitution mutations at one or more of the positions 13, 14, 28, 32 and 35. Additionally, the sequence of the polypeptide according to the invention may comprise substitution mutations at one or more of the positions 9, 10, 11, 17, 18, 24, 25 and 27.

The sequence of a polypeptide according to another embodiment of the invention corresponds to SEQ ID NO:1, comprising at least a substitution mutation at position 13 from phenylalanine to tyrosine.

The sequence of a polypeptide according to another embodiment of the invention corresponds to SEQ ID NO:1,

comprising at least a substitution mutation at position 14 from tyrosine to tryptophan.

5 The sequence of a polypeptide according to another embodiment of the invention corresponds to SEQ ID NO:1, comprising at least a substitution mutation at position 28 from asparagine to arginine.

10 The sequence of a polypeptide according to another embodiment of the invention corresponds to SEQ ID NO:1, comprising at least a substitution mutation at position 32 from glutamine to arginine.

The sequence of a polypeptide according to another embodiment of the invention corresponds to SEQ ID NO:1, comprising at least a substitution mutation at position 35 from lysine to tyrosine.

15 A preferred polypeptide according to the invention corresponds to SEQ ID NO:1, comprising at least the following mutations: F13Y, Y14W, N28R, Q32R and K35Y.

20 Examples of specific sequences of different embodiments of the polypeptide according to the invention, each comprising one or more of the specific mutations described above, are set out in SEQ ID NO:2-5 and illustrated in Figure 1.

25 As an alternative to using the unmodified SPA domain, the SPA domain may also be subjected to mutagenesis in order to increase the stability thereof in alkaline conditions. Such stabilization involves the site-directed substitution of any asparagine residues appearing in the unmodified sequence with amino acid residues that are less sensitive to alkaline conditions. When using the
30 polypeptide according to the invention as an affinity ligand in affinity chromatography, this property of having a reduced sensitivity to alkali provides benefits; affinity chromatography columns are frequently subjected to harsh alkali treatment for cleaning in place (CIP) between separation runs, and the ability to withstand such
35 treatment prolongs the useful lifetime of the affinity chromatography matrix. As an example, making use of pro-

tein Z as starting point, the polypeptide according to the invention may, in addition to the substitution mutations conferring HER2 binding, have modifications in that at least one asparagine residue selected from N3, N6, N11, N21, N23, N28, N43 and N52 has been substituted with an amino acid residue that is less sensitive to alkaline treatment. Non-limiting examples of such polypeptides are those having the following sets of mutations (with respect to the sequence of Z_{wt}): N3A; N6D; N3A, N6D and N23T; N3A, N6D, N23T and N28A; N23T; N23T and N43E; N28A; N6A; N11S; N11S and N23T; N6A and N23T. Thus, these SPA domains, as well as other SPA domains that have been subjected to asparagine mutation for stability reasons, may all be subjected to further substitution mutation of amino acid residues in order to obtain the HER2 binding polypeptide of the invention. Alternatively, an HER2 binding polypeptide of the invention which comprises asparagine residues may be subjected to further mutation to replace such residues. Evidently, this latter alternative is only possible to the extent that the HER2 binding capability of such a molecule is retained.

The invention also encompasses polypeptides that have been derived from any of the polypeptides described above, through generation of a fragment of the above polypeptides, which fragment retains HER2 affinity. The fragment polypeptide is such that it remains stable, and retains the specificity to bind HER2. The possibility to create fragments of a wild-type SPA domain with retained binding specificity to immunoglobulin G is shown by Braisted AC and Wells JA et al in Proc Natl Acad Sci USA 93:5688-5692 (1996). By using a structure-based design and phage display methods, the binding domain of a three-helix bundle of 59 residues was reduced to a resulting two-helix derivative of 33 residues. This was achieved by stepwise selection of random mutations from different regions, which caused the stability and binding affinity to be iteratively improved. Following the same reasoning

with the polypeptides according to the first aspect of the invention, the skilled man would be able to obtain a "minimized" HER2 binding polypeptide with the same binding properties as that of the "parent" HER2 polypeptide.

- 5 Hence, a polypeptide constituting a fragment of a polypeptide according to the above aspect of the invention, which fragment retains binding affinity for HER2, is a further aspect of the invention.

- 10 Another aspect of the present invention relates to a nucleic acid molecule comprising a sequence which encodes a polypeptide according to the invention.

- A further aspect of the present invention relates to an expression vector comprising the nucleic acid molecule of the previous aspect, and other nucleic acid elements
15 that enable production of the polypeptide according to the invention through expression of the nucleic acid molecule.

- Yet another aspect of the present invention relates to a host cell comprising the expression vector of the
20 previous aspect.

- The latter three aspects of the invention are tools for the production of a polypeptide according to the invention, and the skilled person will be able to obtain them and put them into practical use without undue burden, given the information herein concerning the polypeptide that is to be expressed and given the current level
25 of skill in the art of recombinant expression of proteins. As an example, a plasmid for the expression of unmodified protein Z (see e g Nilsson B et al (1987), *supra*) may be used as starting material. The desired substitution mutations may be introduced into this plasmid, using known techniques, to obtain an expression vector in
30 accordance with the invention.

- However, the polypeptide according to the invention
35 may also be produced by other known means, including chemical synthesis or expression in different prokaryotic or eukaryotic hosts, including plants and transgenic ani-

- mals. When using chemical polypeptide synthesis, any of the naturally occurring amino acid residues in the polypeptide as described above may be replaced with any corresponding, non-naturally occurring amino acid residue or derivative thereof, to the extent that the HER2 binding capacity of the polypeptide is not substantially affected. Such non-classical amino acids, or synthetic amino acid analogs, include, but are not limited to, the D-isomers of the common amino acids, α -amino isobutyric acid, 4-amino butyric acid, 2-amino butyric acid, 6-amino hexanoic acid, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β -alanine, fluoroamino acids, designer amino acids such as β -methyl amino acids, α -methyl amino acids, $N\alpha$ -methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid residues can be present in D or L form.
- 20 The present invention also concerns different aspects of using the above-described HER2 binding polypeptide, as well as various methods for treatment, diagnosis and detection in which the polypeptide is useful due to its binding characteristics. When referring to the "HER2
- 25 binding polypeptide" in the following description of these uses and methods, this term is intended to encompass the HER2 binding polypeptide alone, but also all those molecules based on this polypeptide described above that e g constitute fragments thereof and/or incorporate
- 30 the HER2 binding polypeptide as a moiety in a fusion protein and/or are conjugated to a label or therapeutic agent and/or are provided with additional amino acid residues as a tag or for other purposes. As explained above, such fusion proteins, derivatives, fragments etc
- 35 form a part of the present invention.

Thus, in one such aspect, the invention provides use of the HER2 binding polypeptide as described herein as a medicament.

5 In a further aspect, the invention provides use of the HER2 binding polypeptide as described herein in the preparation of a medicament for the treatment of at least one form of cancer characterized by overexpression of HER2. One particular form of cancer characterized by overexpression of HER2 is a breast cancer. As described
10 in the Background section, approximately 25 % of all breast cancer patients show an overexpression of HER2 (Slamon DJ et al, *supra*).

Without wishing to be bound by this theory, the polypeptide described herein is thought to be useful as a
15 therapeutic agent based on at least one of the following mechanisms: (i) Potentiation of chemotherapy (cytotoxic), in that administration of the polypeptide will function in synergy with existing and coming chemotherapies and hormonal therapies. Blocking of the HER2 protein on cell
20 surfaces has been shown to prevent DNA repair following the impact of DNA-damaging drugs (Pietras RJ et al (1994) *Oncogene* 9:1829-1838). (ii) Inhibition of the proliferation of tumor cells (cytostatic). This reasoning is based on the observation that downregulation of HER2 protein
25 occurs when a molecule (antibody) attaches to the HER2 protein on the cell surface, causing some receptors to be endocytosed, limiting the signal for further cell growth (Baselga J et al (1998) *Cancer Res* 58:2825-2831; Sliwkowski MX et al, *supra*).

30 A related aspect of the present invention is the provision of a method for the treatment of at least one form of cancer characterized by overexpression of HER2, which method comprises administering to a subject in need of such treatment a therapeutically effective amount of a
35 composition, which comprises a HER2 binding polypeptide as described herein as an active substance.

The HER2 binding properties of the polypeptide according to the invention, together with the suitability of the polypeptide for the creation of fusion proteins and/or labeled binding molecules, means that the polypeptide may also be useful for targeting of other active substances to the site of a tumor which comprises cells that overexpress HER2. Thus, another aspect of the present invention is the provision of use of the HER2 binding polypeptide as described herein in conjugated to an substance with anti-cancer activity for delivery of said substance to cells that overexpress HER2. The conjugated substance may also be one that functions to elicit a response of the subject's endogenous immune system. Natural killer (NK) cells, or other effectors of the immune system, may be attracted to the complex of HER2 and HER2 binding polypeptide on the cell's surface through the provision of a fusion moiety that serves the function of recruiting such effectors. The NK cells or other effectors, having detected that the cell is abnormal, attach to the HER2 binding fusion protein. Eventually, the cancer cell is consumed by the NK cells (Sliwkowski MX et al, supra; Pegram MD et al (1997) Proc Am Assoc Cancer Res 38:602, Abstract 4044).

Such an active substance may be a protein coupled to the HER2 binding polypeptide by fusion or by chemical linkage, such as chosen among effector enzymes for "ADEPT" (antibody-directed enzyme prodrug therapy) applications; proteins for recruitment of effector cells and other components of the immune system; cytokines, such as IL-2, IL-12, TNF α , IP-10; procoagulant factors, such as tissue factor, von Willebrand factor; toxins, such as ricin A, *Pseudomonas* endotoxin, calcheamicin, maytansinoid. Alternatively, the active substance may be a cytotoxic drug, such as auristatin analogs or doxorubicin, or a radioactive isotope (e g ^{90}Y , ^{131}I , ^{211}At), which isotope may be associated with the HER2 binding polypeptide di-

rectly, or associated via a chelating agent, such as the well known chelators DOTA or DTPA.

5 In a related aspect, the invention also provides a method of directing a substance having an anti-cancer activity to cells overexpressing HER2 *in vivo*, comprising administering a conjugate of said active substance and a HER2 binding polypeptide as described herein to a patient. The conjugate is suitably as described in the preceding paragraph.

10 Another aspect of the present invention is the use of the HER2 binding polypeptide as described herein for the detection of HER2 in a sample. For example, such detection may be performed with the aim of diagnosing disease states characterized by overexpression of HER2. The
15 detection of HER2 presence in a sample may be performed *in vitro* or *in vivo*. A preferred option for *in vivo* diagnosis is the use of positron emission tomography, PET. The sample in question may e g be a biological fluid sample or a tissue sample. A common method, in use today
20 with antibodies directed against HER2, which method may be adapted for use with the HER2 binding polypeptide of the present invention, is histochemical detection of HER2 presence used for identification of HER2 protein overexpression in fresh, frozen, or formalin-fixed, paraffin-
25 embedded tissue samples. For the purposes of HER2 detection, the polypeptide according to the invention may again be used as part of a fusion protein, in which the other domain is a reporter enzyme or fluorescent enzyme. Alternatively, it may be labeled with one or more fluorescent agent(s) and/or radioactive isotope(s), optionally via a chelator. Suitable radioactive isotopes include ^{68}Ga , ^{76}Br , ^{111}In , ^{99}Tc , ^{124}I and ^{125}I .

30 Yet another aspect of the present invention is constituted by the use of an HER2 binding polypeptide as described herein in a method of detecting HER2 in a biological fluid sample. This method comprises the steps of
35 (i) providing a biological fluid sample from a patient to

be tested, (ii) applying an HER2 binding polypeptide as described herein to the sample under conditions such that binding of the polypeptide to any HER2 present in the sample is enabled, (iii) removing non-bound polypeptide, and (iv) detecting bound polypeptide. The amount of the detected bound polypeptide is correlated to the amount of HER2 present in the sample. In step (ii), the application of HER2 binding polypeptide to the sample may be performed in any suitable format, and includes for example the situation when the HER2 binding polypeptide is immobilized on a solid support with which the sample is brought into contact, as well as set-ups in which the HER2 binding polypeptide is present in solution.

Another, related, aspect of the present invention is a method for the detection of HER2 in a sample, comprising the steps of (i) providing a tissue sample suspected of containing HER2, for example a cryostat section or a paraffin-embedded section of tissue, (ii) applying an HER2 binding polypeptide according to the invention to said sample under conditions conducive for binding of the polypeptide to any HER2 present in the sample, (iii) removing non-bound polypeptide, and (iv) detecting bound polypeptide. The amount of the detected bound polypeptide is correlated to the amount of HER2 present in the sample.

Also provided by the present invention is a kit for diagnosis of HER2 overexpression in a tissue sample, comprising the HER2 binding polypeptide according to the invention fused to a reporter enzyme (such as alkaline phosphatase or horseradish peroxidase), reagents for detection of enzyme activity, and positive and negative control tissue slides.

Also provided by the present invention is a kit for diagnosis of HER2 overexpression in a tissue sample, comprising the HER2 binding polypeptide according to the invention fused to a tag for detection by an antibody (such as a flag tag or myc tag), a primary antibody specific

for the tag, a secondary antibody specific for the primary antibody and conjugated to a reporter enzyme, reagents for detection of enzyme activity, and positive and negative control tissue slides.

- 5 One area in diagnosis applications is the in vivo detection of cancer cells or aggregates thereof. The invention provides a kit for performing such diagnosis, which kit comprises the HER2 binding polypeptide according to the invention labeled with a chelator, a diagnostic radioactive isotope (non-limiting examples are ^{68}Ga , ^{76}Br , ^{111}In , ^{99}Tc , ^{124}I and ^{125}I), and reagents for the analysis of the incorporation efficiency.

- 10 As described above, the invention encompasses use of the HER2 binding polypeptide according to the invention to target active substances to cells that overexpress HER2, such as certain types of cancer cells. The invention also provides a kit for this purpose, comprising HER2 binding polypeptide according to the invention labeled with a chelator, a therapeutic radioactive isotope (non-limiting examples are ^{90}Y , ^{131}I , ^{211}At), and reagents for the analysis of the incorporation efficiency.

Brief description of the drawings

- 25 Figure 1 shows an alignment of the sequences of the sequence listing. The amino acid positions that have been subjected to modification in the polypeptides Z_{HER2} according to the invention (represented by SEQ ID NO:2-5) are indicated in bold.

- 30 Figure 2 is a schematic illustration of the amino acid sequence of a fusion polypeptide produced in the Example. Z_{HER2} represents an antigen binding domain with a sequence selected from SEQ ID NO:2-3 and His₆ represents a hexahistidyl tag.

- 35 Figure 3 shows the result of gel electrophoresis of purified fusion proteins. Lane 1: His₆-Z_{HER2} A (8.7 kDa); Lane 2: His₆-Z_{HER2} B (8.7 kDa); M: Molecular weight marker (LMW-SDS Marker Kit, Amersham Biosciences #17-0446-01).

Figure 4 shows Biacore sensorgrams obtained after injection of 10 μ M of the His₆-Z_{HER2} A fusion protein over sensor chip surfaces having A: HER2, B: HIV-1 gp120, and C: BB immobilized thereto.

5 Figure 5 shows Biacore sensorgrams obtained after injection of 10 μ M of the His₆-Z_{HER2} B fusion protein over sensor chip surfaces having A: HER2, B: HIV-1 gp120, and C: BB immobilized thereto.

10 Figure 6 shows Biacore sensorgrams obtained after injection of A: 1 μ M; B: 2 μ M; C: 5 μ M; D: 10 μ M, E: 20 μ M; F: 40 μ M of the His₆-Z_{HER2} A fusion protein over a sensor chip surface having HER2 immobilized thereto.

15 Figure 7 shows Biacore sensorgrams obtained after injection of A: 1 μ M; B: 2 μ M; C: 5 μ M; D: 10 μ M, E: 20 μ M; F: 40 μ M of the His₆-Z_{HER2} B fusion protein over a sensor chip surface having HER2 immobilized thereto.

20 Figure 8A shows Biacore sensorgrams obtained after injection of His₆-Z_{HER2} A over a HER2-ECD flow-cell surface at selected concentrations; 312.5 nM (filled diamonds), 156.3 nM (filled circles), 78.2 nM (filled triangles), 39.1 nM (open squares), 19.6 nM (open diamonds), and 9.8 nM (open circles).

25 Figure 8B shows Biacore sensorgrams obtained after injection of His₆-Z_{HER2} B over a HER2-ECD flow-cell surface at selected concentrations; 625 nM (filled squares), 312.5 nM (filled diamonds), 156.3 nM (filled circles), 78.2 nM (filled triangles), 39.1 nM (open squares), and 19.6 nM (open diamonds).

30 Figure 9 shows specificity of the His₆-Z_{HER2} A binding to SKBR-3 cells. ¹²⁵I-labelled His₆-Z_{HER2} A was allowed to bind to SKBR-3 cells with an estimated theoretical ligand:HER2 receptor ratio of 5:1. Values are means of three measurements. Error bars represent standard deviations.

35 Figure 10 shows Biacore sensorgrams obtained after injection of purified His₆-Z_{HER2} A (open squares) and His₆-(Z_{HER2} A)₂ (filled squares) over a sensor chip flow-cell

surface containing amine-coupled HER2-ECD. The γ values of the curves have been normalized to between 0 and 100 Resonance Units. The inserted SDS-PAGE gel (Tris-Glycine 16% homogenous gel, reducing conditions) shows the expressed and IMAC-purified His₆-Z_{HER2} A (lane 1) and His₆-(Z_{HER2} A)₂ (lane 2). Lane M, marker proteins with molecular masses in kilodaltons.

Figure 11 shows a comparison of biodistribution of radioactivity in tumor bearing nude mice 1 h after injection of ¹²⁵I-benzoate-(Z_{HER2} A)₂. Blocked: Data for mice pre-injected with non-labeled (Z_{HER2} A)₂. Non-blocked: Data for mice without pre-injection.

Figure 12 shows a comparison of biodistribution of radioactivity in tumor bearing nude mice 4 h after injection of ¹²⁵I-benzoate-(Z_{HER2} A)₂ (Z4dimer) or ¹²⁵I-benzoate-Z_{Taq} (Z_{Taq}4:5).

Figure 13 shows the biodistribution of radioiodine in tumor bearing nude mice at various time points after injection of ¹²⁵I-benzoate-(Z_{HER2} A)₂. Data are combined from two biodistribution experiments. Data for 4 h pi are averages from both experiments.

Figure 14 shows the biodistribution of radioiodine in tumor bearing nude mice 8 h after injection of ¹²⁵I-benzoate-(Z_{HER2} A)₂.

Figure 15 shows a comparison of radioactivity concentration in blood and tumors. Data are combined from two biodistribution experiments. A: experimental data. B: curves fitted using non-linear regression with a two-phase exponential decay model.

Figure 16 shows the tumor to blood ratio of radioactivity concentration. Data are combined from two biodistribution experiments.

Figure 17 is a whole body γ -camera image of tumor bearing mice (SKOV-3) 6 h (left mouse) and 8 h (right mouse) after iv tail injection of ¹²⁵I-benzoate-(Z_{HER2} A)₂ conjugate.

The invention will now be illustrated further through the non-limiting recital of experiments conducted in accordance therewith.

5

Example 1Selection and study of HER2 binding polypeptides

In these experiments, several HER2 binding polypeptides according to the invention were selected from a library of a multitude of different SPA domain related polypeptides, and subsequently characterized.

Library panning and clone selection

A combinatorial phage display library was prepared essentially as described in Nord K et al (1995, *supra*). The pool of this library which was used in the present study comprised 8.7×10^8 variants of protein Z (Affibody® molecules), with random amino acid residues at positions 9, 10, 11, 13, 14, 17, 18, 24, 25, 27, 28, 32 and 35. Antigen binding Affibody® molecules were selected in four panning cycles using biotinylated human HER2 extracellular domain (HER2-ECD) as the target (recombinant human HER2 extracellular domain, amino acids 238-2109, provided by Fox Chase Cancer Center, Philadelphia, USA). From the outcome of the four selection cycles, 91 clones were picked for phage ELISA in order to perform an analysis of their HER2 binding activity.

Phage ELISA for analysis of HER2 binding

Phages from the clones obtained after four rounds of selection were produced in 96 well plates, and an Enzyme Linked ImmunoSorbent Assay (ELISA) was used for screening for phages expressing HER2 binding Affibody® molecules. Single colonies were used to inoculate 250 µl TSB medium (30.0 g Tryptic Soy Broth (Merck), water to a final volume of 1 l, autoclaved) supplemented with 2 % glucose and 100 µg/ml ampicillin in a deep well 96 well plate and

grown on a shaker over night at 37 °C. 5 µl overnight culture was added to 500 µl TSB+YE medium (30.0 g Tryptic Soy Broth (Merck), 5.0 g yeast extract, water to a final volume of 1 l, autoclaved) supplemented with 0.1 % glucose and 100 µg/ml ampicillin in a new plate. After growing at 37 °C for 3 h, 0.5 µl of 5×10^{12} pfu/ml (2.5×10^9 pfu) helper phage M13K07 (New England Biolabs, #NO315S) and 100 µl TSB+YE medium were added to each well, and the plates were incubated without shaking at 37 °C for 30 minutes. 300 µl TSB+YE supplemented with IPTG, kanamycin and ampicillin were added to each well to a final concentration of 1 mM IPTG, 25 µg/ml kanamycin and 100 µg/ml ampicillin, and the plates were incubated on a shaker overnight at 30 °C. Cells were pelleted by centrifugation at 2500 g for 15 minutes and supernatants, containing phages expressing Affibody® molecules, were used in ELISA. 100 µl of 4 µg/ml of HER2 in PBS (2.68 mM KCl, 137 mM NaCl, 1.47 mM KH_2PO_4 , 8.1 mM Na_2HPO_4 , pH 7.4) were added to a microtiter plate (Nunc #446612) and incubated for 1 month at 4 °C. After blocking wells with 2 % skim milk powder in PBS (blocking buffer) for 1 h at room temperature, 200 µl phage-containing supernatant and 50 µl 10 % blocking buffer were added. The plates were incubated for 2 h at room temperature. A polyclonal antibody (rabbit anti-M13, Abcam #ab6188) was diluted 1:1000 in 2 % blocking buffer, and 150 µl were added to each well. The plate was incubated at room temperature for 1 h. A goat anti-rabbit IgG antibody conjugated with alkaline phosphatase (Sigma #A-3687) was diluted 1:10000 in 2 % blocking buffer, after which 150 µl were added to each well and incubated for 1 h at room temperature. Developing solution was prepared by dissolving Sigma-104 substrate (Sigma #104-105) in a 1:1 mixture of 1 M diethanolamine, 5 mM MgCl_2 , pH 9.8 and water (1 tablet/5 ml of 1:1 mixture). Thereafter, 180 µl of the developing solution were added to each well. Wells were washed twice with PBS-T (PBS + 0.1 % Tween-20) and once with PBS be-

fore addition of each new reagent. 25 minutes after addition of substrate, the plates were read at A₄₀₅ in an ELISA spectrophotometer (Basic Sunrise, Tecan).

Phages encoding HER2 binders were identified using a threshold criterion of an ELISA value of A₄₀₅ above 0.5. 48 clones gave an ELISA signal above this value, and were selected for DNA sequence analysis, together with 5 clones selected at random for which no ELISA results were available.

10

DNA sequence analysis

Sequencing of the DNA from the clones isolated according to the procedure above was performed with the ABI PRISM®, BigDye™ Terminator v2.0 Ready Reaction Cycle Sequencing Kit (Applied Biosystems) according to the manufacturer's recommendations. Plasmids were prepared and DNA encoding the Affibody® molecules was sequenced using the oligonucleotides RIT-27 (5'-GCTTCCGGCTCGTATGTTGTGTG-3') and the biotinylated NOKA-2 (5'-biotin-CGGAACCAGAGCC-ACCACCGG-3'). The sequences were analyzed on an ABI PRISM® 3700 Genetic Analyser (Applied Biosystems). From the 53 clones previously selected, several clones were found to encode the same amino acid sequence. Taking these degeneracies into account, four sequences of Affibody® molecules expressed by clones selected in the ELISA binding assay are given in Figure 1 (Z_{HER2} A-D), and identified in the sequence listing as SEQ ID NO:2-5.

25

Cloning and protein production

30

Z_{HER2} polypeptides were expressed in *E. coli* cells, using expression vectors encoding constructs that are schematically illustrated in Figure 2. The polypeptides were thereby produced as fusions to an N-terminal hexahistidyl tag. The fusion polypeptides His₆-Z_{HER2} A and His₆-Z_{HER2} B were purified on Immobilized Metal ion Affinity Chromatography (IMAC) columns and analyzed on SDS-PAGE.

35

Ink. t. Patent- och reg.verket

2004-02-09

28

Hansellman Kassan

The result of the SDS-PAGE experiment is given in Figure 3.

Biosensor analysis of fusion polypeptides

5 The interactions between the His-tagged Z_{HER2} variants produced according to the preceding section and HER2 were analyzed using surface plasmon resonance in a Biacore® 2000 system (Biacore AB, Uppsala, Sweden). Human HER2, HIV-1 gp120 (Protein Sciences Corporation, #2003-
10 MN), and BB (albumin-binding protein derived from streptococcal protein G), the latter two for use as controls, were immobilized in different flow cells by amine coupling onto the carboxylated dextran layer on surfaces of CM-5 chips, according to the manufacturer's recommenda-
15 tions. Immobilization of human HER2, HIV-1 gp120, and BB resulted in 1900, 6290, and 1000 resonance units (RU), respectively. A fourth flow cell surface was activated and deactivated for use as blank during injections. The His₆-Z_{HER2} A and His₆-Z_{HER2} B proteins were diluted in HBS (5
20 mM HEPES, 150 mM NaCl, 3.4 mM EDTA, 0.005 % surfactant P-20, pH 7.4) to a final concentration of 10 µM, and injected in random order as duplicates at a constant flow-rate of 30 µl/minute. The ability of the purified proteins His₆-Z_{HER2} A and His₆-Z_{HER2} B to interact with HER2 was
25 confirmed, as illustrated by the sensorgrams of Figures 4 and 5, respectively.

Furthermore, kinetic studies were performed for His₆-Z_{HER2} A and His₆-Z_{HER2} B. The CM-5 chip having 1900 RU of human HER2 immobilized thereto was used. A series of six
30 different concentrations (1 µM - 40 µM) of HER2 binding polypeptide was prepared in HBS for each of His₆-Z_{HER2} A and His₆-Z_{HER2} B, and injected in random order as duplicates at a flow-rate of 30 µl/minute. The total injection time was 50 seconds (association) followed by a wash during 6 minutes (dissociation). The surfaces were regenerated with 20 mM HCl for 10 seconds. The responses measured in reference cells (activated/deactivated surface)
35

were subtracted from the response measured in the cells with immobilized HER2. The binding curves (sensorgrams) were analyzed using the 1:1 Langmuir binding model of the BIAevaluation 3.0.2 software (Biacore AB). As is clear from the binding curves presented in Figures 6 (His₆-Z_{HER2} A) and 7 (His₆-Z_{HER2} B), His₆-Z_{HER2} A and His₆-Z_{HER2} B both clearly bind to HER2, as evidenced by the association and dissociation curves with an indicated K_D of 10-100 nM for His₆-Z_{HER2} A and 200-400 nM for His₆-Z_{HER2} B. Furthermore, the binding is selective, since neither of the HER2 binding polypeptides studied bind to the BB and gp120 control antigens (Figures 4 and 5).

In a second kinetic experiment, the His₆-Z_{HER2} A and His₆-Z_{HER2} B variants were again injected over the HER2 surface at different concentrations (0-5 µM, with 0.0098 µM as the lowest concentration for His₆-Z_{HER2} A and 0.0196 µM for His₆-Z_{HER2} B, diluted in HBS) with a flow rate of 30 µl/min. Prior to the kinetic analysis, the protein concentration had been determined by amino acid analysis. The dissociation equilibrium constant (K_D), the association rate constant (k_a), and the dissociation rate constant (k_d) were calculated using BIAevaluation 3.2 software (Biacore), assuming a one-to-one binding. For the first two Biacore analyses, the samples were run at 25 °C in duplicates in random order, and after each injection the flow cells were regenerated by the injection of 10 mM HCl. Upon evaluation of the binding curves (Figure 8A-8B), the dissociation equilibrium constant (K_D) was determined to be about 50 nM for His₆-Z_{HER2} A and about 140 nM for His₆-Z_{HER2} B. The reason for the difference in K_D is most likely due to the marked difference in dissociation rate, as can be seen by comparing Figure 4, diagram A with Figure 5, diagram A. For His₆-Z_{HER2} A, the association rate constant (k_a) was calculated to be about $1.8 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$ and the dissociation rate constant (k_d) about $9.9 \times 10^{-3} \text{ s}^{-1}$, while for His₆-Z_{HER2} B, k_a and k_d were difficult to estimate due to the fast association and disso-

ciation kinetics. Thus, the His₆-Z_{HER2} A affibody variant, showing stronger binding to its target, was selected for further characterization.

5

Example 2Binding of Z_{HER2} A to cells expressing HER2Cell culture

The human breast cancer cell line SKBR-3, known to
10 express about 2×10^6 HER2 molecules per cell, was purchased from ATCC (ATCC #HTB-30). The cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and PEST (100 IU/ml penicillin and 100 µg/ml streptomycin), all from Biochrom KG (Ber-
15 lin, Germany). The cells were cultured at 37 °C in humidified air containing 5 % CO₂, and seeded in 3 cm petri dishes three days before the experiment.

Radiolabeling

20 Labeling precursor, N-succinimidyl p-(trimethylstannyl)benzoate (SPMB), was prepared according to Orlova et al in Nucl Med Biol 27:827-835 (2000), and 5 µg of SPMB was added to 5 MBq of ¹²⁵I in a 5 % solution of acetic acid. To start the reaction, 40 µg of chloramine-T
25 (Sigma, St. Louis, MO) in aqueous solution was added. The reaction mixture was agitated for 5 min, and 80 µg of sodium-meta-bisulphate (Aldrich, Steinheim, Germany) in aqueous solution was added to stop the reaction. The radiolabeled precursor was added to 40 µg of His₆-Z_{HER2} A or
30 His₆-Z_{HER2} B in 0.07 M borate buffer, pH 9.2. The coupling reaction was performed at room temperature for 45 min with continuous shaking. Labeled Z_{HER2} variants were separated from low molecular weight products using a NAPTM-5 size exclusion column (Amersham Biosciences) equilibrated
35 with PBS. The radiolabeled Z_{HER2} variants were then analyzed using Biacore technology to verify that the labeling procedure had not affected the binding affinity to-

wards HER2-ECD. Both Z_{HER2} variants showed retained affinity (data not shown).

Cellular tests

5 To each dish of about 100000 SKBR-3 cells, 14 ng of
labeled His₆-Z_{HER2} A or His₆-Z_{HER2} B in 1 ml complemented me-
dium was added. This amount corresponds to a theoretical
ligand:receptor ratio of 5:1. Three dishes without cells
10 were treated in the same way, in order to determine un-
specific binding not derived from cells. This value was
subtracted from all others. To analyze the specificity of
cell binding, three dishes were treated not only with la-
beled Z_{HER2} variants, but also with a 500-fold excess of
unlabeled Z_{HER2} variants. After three hours of incubation
15 at 37 °C, the radioactive medium was removed and the
dishes were washed rapidly three times with ice-cold se-
rum-free medium. Cells were trypsinated with 0.5 ml Tryp-
sin/EDTA solution (0.25 %/0.02 % in PBS; Biochrom KG,
Berlin, Germany) for 15 min at 37 °C. The cells were then
20 resuspended in 1 ml complemented medium, and 0.5 ml of
the cell suspension was used for cell counting and the
remaining 1 ml was used for radioactivity measurement in
an automated γ counter.

As presented in Figure 9, His₆-Z_{HER2} A showed specific
25 binding to SKBR-3 cells, known to express 2×10^6 HER2
receptors per cell ("non-blocked" bar). The binding of
radiolabeled His₆-Z_{HER2} A could be totally blocked by the
addition of an excess of non-labeled His₆-Z_{HER2} A
("blocked" bar). However, the binding of His₆-Z_{HER2} B to
30 SKBR-3 cells was below the detection limit (data not
shown), probably as a result of the faster dissociation
rate for this Z_{HER2} variant (cf above).

Brilliant Blue staining. Upon SDS-PAGE analysis, the protein was observed as a specific band of the expected molecular weight (15.6 kD) (Figure 10, Lane 2 of insert). Estimations from absorbance measurements at 280 nm demonstrated an expression level of about 200 mg/l of cell culture.

Biosensor analysis

A Biacore® 2000 instrument (Biacore AB) was used for real-time biospecific interaction analysis (BIA). A recombinant extracellular domain of HER2 (HER2-ECD), diluted in 10 mM NaAc, pH 4.5, was immobilized (about 2200 RU) on the carboxylated dextran layer of one flow-cell surface of a CM5 sensor chip (research grade) (BR-1000-14, Biacore AB) by amine coupling according to the manufacturer's instructions. Another flow-cell surface was activated and deactivated, to serve as a reference surface. For the Z_{HER2} sample, the buffer was changed to HBS (5 mM HEPES, 150 mM NaCl, 3.4 mM EDTA, 0.005 % surfactant P20, pH 7.4) by gel filtration using a NAP™-10 column, according to the manufacturer's protocol (Amersham Biosciences), and the sample was thereafter filtrated (0.45 µm; Millipore, Billerica, MA). Binding analyses were performed at 25 °C, and HBS was used as running buffer. For all Biacore analyses, the samples were run in duplicates in random order, and after each injection the flow cells were regenerated by the injection of 10 mM HCl.

In a first experiment, difference in binding to HER2-ECD between the monomeric and the dimeric Z_{HER2} proteins (His₆-Z_{HER2} A of Example 1 and His₆-(Z_{HER2} A)₂) was tested by injection of 5 µM of each protein over the HER2-ECD surface, with a flow rate of 5 µl/min. As can be seen in Figure 10, a slower off-rate was observed for His₆-(Z_{HER2} A)₂, indicating a stronger binding between HER-ECD and His₆-(Z_{HER2} A)₂, compared to His₆-Z_{HER2} A.

In a second experiment, His₆-(Z_{HER2} A)₂ was subjected to a kinetic analysis, in which the protein was injected

over the HER2-ECD surface at different concentrations (0-5 μ M, with 0.0049 μ M as the lowest concentration, diluted in HBS) with a flow rate of 30 μ l/min. Prior to the kinetic analysis, the protein concentration had been determined by amino acid analysis. The dissociation equilibrium constant (K_D), the association rate constant (k_a), and the dissociation rate constant (k_d) were calculated using BIAevaluation 3.2 software (Biacore AB), assuming 1:1 binding. Upon evaluation of the binding curves, the dissociation equilibrium constant (K_D) was determined to be about 3 nM, the association rate constant (k_a) was calculated to be about $2.5 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$ and the dissociation rate constant (k_d) about $7.6 \times 10^{-4} \text{ s}^{-1}$ (Table 1). These values can be compared to the kinetic constants obtained for the monomeric His₆-Z_{HER2} A of Example 1, confirming the stronger binding of the dimeric His₆-(Z_{HER2} A)₂. Such improved apparent higher affinity, due to avidity effects for the dimeric constructs, have been demonstrated earlier for other Affibody® molecules (Gunneriusson E et al, Protein Eng 12:873-878 (1999)).

Example 4

Biodistribution and tumor targeting with (Z_{HER2})₂ in nude mice bearing SKOV-3 xenografts

In the experiments making up this example, the dimeric (Z_{HER2} A)₂ polypeptide according to Example 3 was radiolabeled with ¹²⁵I and injected into mice bearing a grafted tumor characterized by HER2 overexpression. Studies of the biodistribution of the polypeptide were conducted, as well as imaging of the injected mice to study localization of the labeled polypeptide. A labeled Z domain derivative with binding affinity for Taq DNA polymerase was used as control without specificity for HER2 (Z_{Taq}; described in Gunneriusson E et al, supra and referred to therein as Z_{Taq} s1-1).

Materials and methodsIndirect radiolodination of (Z_{HER2}A)₂

- 5 A volume of 2,3 µl ¹²⁵I (corresponding to 10 MBq) (Na[¹²⁵I], Amersham Biosciences, Uppsala, Sweden) was added to a siliconized microcentrifuge tube. 10 µl acetic acid (0,1 % in water), 5 µl N-succinimidyl p-trimethylstannyl-benzoate (1 mg/ml in 5 % acetic acid in methanol)
- 10 (prepared according to Koziorowski J et al, Appl Radiat Isot 49:955-959 (1998)) and 10 µl Chloramine-T (4 mg/ml in water) (CH₃C₆H₄SO₂N(Cl)Na·3H₂O, Sigma, St Louis, MO, USA) was added. The reaction was allowed to take place for five minutes with some mixing. The reaction was then
- 15 terminated with 10 µl sodium metabisulfate (8 mg/ml in water) (Na₂S₂O₅, Sigma, St Louis, MO, USA). A volume of 40 µl (Z_{HER2}A)₂ dimer (0,25 mg/ml in 0,07 M borate buffer, pH 9,2 (sodium borate, Na₂B₄H₇·10H₂O, Sigma, St Louis, MO, USA, and hydrochloric acid, HCl, Merck, Darmstadt, Ger-
- 20 many)) was added to the reaction tube. Another 40 µl of borate buffer was added to each tube in order to raise the pH to about 9. After a reaction time of 45 minutes with continuous shaking, the reaction components were separated on NAP-5 size exclusion columns (Amersham Bio-
- 25 sciences, Uppsala, Sweden) equilibrated with PBS according to the manufacturer's protocol. The reaction tube, void fraction, high MW fraction, low MW fraction and column were measured at 60 cm (¹²⁵I) with a handheld γ detector (Mini-instruments Ltd, Essex, UK) in order to calcu-
- 30 late the labeling yield. The high molecular weight fraction was stored in siliconized microcentrifuge tube at -20 °C until use the following day. The obtained yield was 25-30 %.

35 Indirect radiolodination of Z_{Tag}

A stock solution of [¹²⁵I]-NaI was mixed with 10 µl 0.1 % aqueous solution of acetic acid, 5 µl of N-

succinimidyl p-trimethylstannyl-benzoate solution (1 mg/ml in 5% acetic acid in methanol), and 10 µl aqueous solution of Chloramine-T (4 mg/ml). The reaction mixture was vigorously vortexed, and incubated during 5 min at room temperature with shaking. The reaction was quenched with 10 µl aqueous solution of sodium metabisulfite (8 mg/ml). 21 µl solution of Z_{Taq} in PBS (2.4 mg/ml) was added to the crude reaction mixture. The pH of the reaction mixture pH was adjusted to about 9 by addition of borate buffer (0.1 M, pH 9.15). The reaction mixture was incubated at room temperature during 30 min with shaking, and separated into high molecular weight fraction (labeled Z_{Taq}) and low molecular weight fraction on a NAP-5 column pre-equilibrated with 5 % albumin (bovine, fraction V, Sigma, St. Louis, MO, USA) in PBS, using PBS as eluent. The obtained radiochemical yield was 75 % and 80 % for protein. The specific radioactivity was 100 kBq/µg.

Animal preparation

Female outbred nu/nu balb mice from M&B (10-12 weeks old when arrived) were used under permission C181/1. Mice were acclimatized in the animal facilities of the Rudbeck laboratory, Uppsala, Sweden, using standard diet, bedding and environment during the week before xenografts were established in them. The mice had free access to food and drinking water.

Two months before the first experiment, 5×10^6 SKOV-3 human ovarian cancer cells (ATCC #HTB-77) were injected subcutaneously in the right hind leg of 33 mice. This group is denoted "Set A".

Three weeks before the second experiment, 10^7 SKOV-3 cells were injected subcutaneously in both hind legs of 32 mice. This group is denoted "Set B".

For imaging studies, two mice with big tumors (see below) were taken from Set A and all others from Set B.

By the time of the experiments, tumors had been established in all mice, but were rather small and differed

in size and status (encapsulated and invasive, stage of vascularization). At the time of use, all mice weighed 22-27 g.

5 Biodistribution Experiment I

20 mice from Set A were randomly divided into 5 groups (I-V) with 4 mice in each group. 2 mice from Set A with bigger tumors were excluded for use in imaging studies. Groups, injections and times of sacrifice were according to Scheme 1.

The mice were injected iv in the tail with 0.5 µg (ZHER2 A)₂, indirectly labeled with ¹²⁵I (100 kBq per mouse) in 50 µl PBS. Mice in group II ("blocked group") were pre-injected sc with 0.05 mg of unlabeled (ZHER2 A)₂ in 200 µl PBS, 45 min before the injection of labeled (ZHER2 A)₂. All injections were tolerated well, judging by the lack of any visible problems.

Scheme 1

Group	Mouse ID	Additional treatment	Time of sacrifice post injection (h)
I	1-4		1
II	5-8	Unlabeled (ZHER2 A) ₂	1
III	9-12		4
IV	13-16		8
V	17-20		24

20 5 min before the time of sacrifice, mice were injected ip with a lethal dose of Ketalar/Rompun solution (20 µl/g body weight, Ketalar 10 mg/ml (Pfizer, New York, USA), Rompun 1 mg/ml (Bayer, Leverkusen, Germany)). Blood was taken at the time of sacrifice by heart puncture with a 1 ml syringe washed with diluted heparin (5000 IE/ml, Leo Pharma, Copenhagen, Denmark). Blood, samples of urine, muscle, bone, large and small intestines, heart, bladder, lung, liver, spleen, pancreas, kidney, stomach, salivary and thyroid glands, brain, tumors and tails were

25

dissected and collected in weighed 20 ml plastic bottles. In the case of multiple tumors in some mice from Set B, every tumor was collected in separate bottle. The samples of organs and tissue were weighed, and their radioactivity measured with a γ -counter (Automated γ -counter with a 3-inch NaI(Tl) detector, 1480 Wallac WIZARD, Wallac OY, Turku, Finland).

Biodistribution Experiment II

24 mice from Set B were randomly divided into 6 groups with 4 mice in each group. 8 mice from Set B with bigger tumors were selected for use in imaging studies. Groups, injections and times of sacrifice were according to Scheme 2.

The mice of groups I and IV-VI were injected iv in the tail with 0.5 μg ($\text{Z}_{\text{HER2}} \lambda$)₂, indirectly labeled with ^{125}I (100 kBq per mouse) in 50 μl PBS. The mice of group II were injected with the same amount of radioiodinated ($\text{Z}_{\text{HER2}} \lambda$)₂, but subcutaneously in the tail. The mice of group III ("negative control group") were injected iv in the tail with 1.07 μg Z_{Taq} indirectly labeled with ^{125}I (100 kBq per mouse) in 50 μl PBS. All injections were tolerated well, judging by the lack of any visible problems.

25

Scheme 2

Group	Mouse ID	Additional treatment	Time of sacrifice post injection (h)
I	1-4	Labeled Z_{Taq}	4
II	5-8		4
III	9-12		4
IV	13-16		6
V	17-20		10
VI	21-24		15

Sacrifice and taking of samples were performed as described above for Biodistribution Experiment I. In this second experiment, the carcass was also collected and its radioactivity content measured. The samples of organs and tissue were weighed, and their radioactivity measured with a γ -counter.

Measurement of radioactivity

A standard protocol for measurement of ^{125}I was used. Counts per minute corrected with background level were used for the evaluation. The tissue uptake value, expressed as %ID/g, percent injected dose per gram tissue, was calculated as

$$\%ID/g = \frac{\text{tissue radioactivity} / \text{injected radioactivity}}{\text{tissue weight}} \times 100$$

wherein for iv injections:

Injected radioactivity = Average radioactivity in control syringes - Radioactivity in used syringe - Radioactivity in tail

and for sc injections:

Injected radioactivity = Average radioactivity in control syringes - Radioactivity in used syringe

Imaging study

For the imaging, mice were divided in two groups with 5 mice in each taking in account that every group would comprise one mouse with a big tumor from Set A. Mice from Set B were randomized. The two groups of mice were injected with 2.3 μg (^{125}I -ZHER2 A)₂ indirectly labeled with ^{125}I (2.9 MBq per mouse) in 90 μl PBS 6 h or 8 h be-

fore imaging, respectively. All injections were tolerated well, judging by the lack of any visible problems.

Whole body imaging of the mice was performed at 6 and 8 h post injection (pi) of radioconjugate. Mice were forced to urinate, anesthetized with lethal Keta-
lar/Rompun injection ip and killed by cervical dislocation. Mice (5 in each group) were placed in an e.CAM γ -camera (Siemens, Germany), and 10 min images were obtained at each time point. Two mice with bigger tumors (1 from each group) were selected for a special image in the same camera, with an exposure of 20 min. The images were acquired in a 256 x 256-bit matrix with a low energy, high resolution collimator in a 35 keV energy window with 99 % window size. The images were evaluated with the aid of Hermes software from Nuclear Diagnostics (Kent, UK).

Results

20 Blocking experiment

The blocking experiment in Biodistribution Experiment I was performed in order to establish whether uptake of $(ZHER2 \lambda)_2$ in tumors was specific and receptor regulated. Before the major iv injection of radioiodinated dimer, 0.05 mg of unlabeled $(ZHER2 \lambda)_2$ was injected sc in the mice of group II of Scheme 1. Uptake of radioactivity at 1 h post injection in group I and group II were compared. Tumor to blood ratios for the two groups of mice were 0.72 (group I, average) and 0.25 (group II, average) (Figure 11). However, the difference in uptake was not significant ($p = 0.16$). In all organs excepting the tumor, radioactivity uptake was the same for both blocked and non-blocked animals.

The rather low tumor to blood ratio in the case of non-blocked mice can be explained by the early time point (1 h pi) chosen for this experiment.

Specificity of uptake

In Biodistribution Experiment II, the mice of group III were injected with an amount of Z_{TaQ} corresponding to the amount of $(Z_{HER2} A)_2$ injected in the mice of the other groups. Z_{TaQ} had been labeled with radioiodine using the same indirect method as for $(Z_{HER2} A)_2$. Z_{TaQ} is non-specific with respect to HER2 receptors. Uptake of radioactivity at 4 h post injection in group I and group III were compared. The results of this experiment (Figure 12) showed that the non-specific Z_{TaQ} molecule had a lower tumor uptake than the specific $(Z_{HER2} A)_2$ molecule. Tumor to blood ratios in this experiment were 1.43 (group I, specific $(Z_{HER2} A)_2$) and 0.15 (group III, unspecific Z_{TaQ}). Statistical analysis showed that the difference was significant ($p = 0.009$). In all other organs, radioactivity uptake was on the same level for both Z molecules.

A higher tumor to blood ratio for $(Z_{HER2} A)_2$ was observed in this experiment, compared to the blocking experiment. This was likely due to the later time point of the experiment (4 h pi).

Biodistribution

The results from the groups of mice in Biodistribution Experiments I and II that had been injected iv with labeled $(Z_{HER2} A)_2$ were combined in an analysis of the biodistribution of radioiodine in organs and tissues of the tumor bearing mice. The results are shown in Figures 13-16.

Referring to Figure 13 and 14, the concentration of ^{125}I in tumors was higher than in most normal organs, indicating that the $(Z_{HER2} A)_2$ polypeptide is able to target tumor cells bearing HER2. The radioactivity concentration in normal organs and tissues was found to be lower than in the tumors, with the exception of kidney (all time points), thyroid (all time points), and liver (early time points). The experiments showed a quick clearance of radioiodine from blood and normal organs. Clearance from

normal organs mainly followed blood clearance, with the exception of the thyroid, where accumulation of radioiodine was found. Elevated thyroid uptake of free iodine, even for indirect labeling methods, is well known and can to some extent be prevented with "cold", or non-radioactive, iodine (Larsen RH et al, Nucl Med Biol 25:351-357 (1998)). High concentrations of radioiodine were also found in the kidneys of the mice, which was also expected since the kidneys are the main excretion pathway for such small proteins and catabolites.

Figures 15A and B show the progression over time of the radioiodine concentration in blood and in tumor. Starting at 4 h pi, tumor radioactivity was higher than blood radioactivity. Using the experimental data as presented in Figure 15A, the half-lives of radioiodine in blood and tumors were calculated using GraphPad Prism®, v 3.0, from GraphPad Software (San Diego, USA). Non-linear regression with a two-phase exponential decay was used as model, and the resulting graphs are presented in Figure 15B. $T_{1/2\alpha}$ for the tumors was shorter (0.36 h) than for blood (0.76 h), but $T_{1/2\beta}$ was longer (87.5 h for tumors vs 4.3 h for blood), which is in good agreement with the obtained results. For comparison, $T_{1/2\alpha}$ in blood for the labeled dimer, calculated with the same model using biodistribution data from normal, non-tumor bearing mice, was 0.3 h (data not shown).

The tumor to blood ratio of radioactivity concentration (Figure 16) increased with time during at least 12 h pi. This ratio is a good estimating factor for imaging contrast, because the main background in radioactivity imaging comes from radioactivity in the blood. Taking into account the tumor to blood ratio and the tumors' radioactivity concentrations, it was concluded that 6 and 8 h pi might be the optimal time points for images. For an image with good contrast, the tumor to non-tumor radioactivity concentration ratio should not be less than 2.

Gamma images

Gamma-images were taken of each of the two groups of 5 mice each selected for imaging (at 6 h and 8 h pi, respectively). In all mice at both time points, kidneys with well-defined structures could be identified. Some additional structure (probably liver) is visible on the image of mice 6 h pi over the kidneys, as well as an elevated background from a generalized blood pool. Some animals had some urine in their bladders, which is also directly visible. On the image with mice 8 h pi, additional structure in the neck area can be identified, which in all likelihood is the thyroid.

From 5 animals in each image session, one large invasive tumor (from the first batch of SKOV-3 injection) was visualized. No other tumor localization was evident. The two animals in question were chosen for an additional imaging session, and the result is shown in Figure 17.

Summary

Biodistribution of the dimer polypeptide (Z_{HER2} A)₂, indirectly labeled with radioiodine (¹²⁵I) via a benzoate group, in mice bearing SKOV-3 (ovarian cancer cell line) tumors showed good agreement with normal biodistribution of the conjugate in normal mice. Tumor uptake of radioiodine injected as ¹²⁵I-benzoate-(Z_{HER2} A)₂ was achieved. The tumor uptake was receptor mediated and specific, as shown by blocking experiments using a pre-injection of a high concentration of non-labeled (Z_{HER2} A)₂ molecule, and by injection of a non-specific, labeled Z variant, Z_{Taq}. Analysis of the data obtained showed that the radioactivity concentration in tumor was higher than the radioactivity concentration in blood after 4 h pi, and higher than in the majority of normal organs and tissues after 6 h pi, except for the kidneys and thyroid. Gamma-images of mice bearing SKOV-3 xenograft tumors were obtained at 6 and 8 h pi. Good resolution was achieved. At both time points, big invasive tumors could be clearly identified.

CLAIMS

1. Polypeptide, which has a binding affinity for
HER2 and which is related to a domain of staphylococcal
protein A (SPA) in that the sequence of the polypeptide
5 corresponds to the sequence of the SPA domain having from
1 to about 20 substitution mutations.
2. Polypeptide according to claim 1, which has a
10 binding affinity for HER2 such that the K_D value of the
interaction is at most 1×10^{-6} M.
3. Polypeptide according to claim 2, which has a
binding affinity for HER2 such that the K_D value of the
15 interaction is at most 1×10^{-7} M.
4. Polypeptide according to any one of claims 1-3,
the sequence of which corresponds to the sequence of SPA
protein Z, as set forth in SEQ ID NO:1, comprising from 1
20 to about 20 substitution mutations.
5. Polypeptide according to claim 4, comprising from
4 to about 20 substitution mutations.
- 25 6. Polypeptide according to claim 4 or 5, comprising
substitution mutations at one or more of the positions
13, 14, 28, 32 and 35.
7. Polypeptide according to claim 6, additionally
30 comprising substitution mutations at one or more of the
positions 9, 10, 11, 17, 18, 24, 25 and 27.
8. Polypeptide according to any one of claims 4-7,
comprising a substitution mutation at position 13 from
35 phenylalanine to tyrosine.

9. Polypeptide according to any one of claims 4-8, comprising a substitution mutation at position 14 from tyrosine to tryptophan.

5 10. Polypeptide according to any one of claims 4-9, comprising a substitution mutation at position 28 from asparagine to arginine.

10 11. Polypeptide according to any one of claims 4-10, comprising a substitution mutation at position 32 from glutamine to arginine.

15 12. Polypeptide according to any one of claims 4-11, comprising a substitution mutation at position 35 from lysine to tyrosine.

20 13. Polypeptide according to any one of claims 4-12, the amino acid sequence of corresponds to that of SEQ ID NO:1, comprising at least the following mutations: F13Y, Y14W, N28R, Q32R and K35Y.

25 14. Polypeptide according to any one of claims 4-13, the amino acid sequence of which is as set out in any one of SEQ ID NO:2-5.

30 15. Polypeptide according to claim 14, the amino acid sequence of which is as set out in any one of SEQ ID NO:2-3.

35 16. Polypeptide according to any preceding claim, in which at least one of the asparagine residues present in the domain of staphylococcal protein A (SPA) to which said polypeptide is related have been replaced with another amino acid residue.

17. Polypeptide according to claim 16, the sequence of said domain of staphylococcal protein A (SPA) corre-

sponding to the sequence of SPA protein 2 as set forth in SEQ ID NO:1, and the polypeptide comprising substitution mutations at at least one position chosen from N3, N6, N11, N21, N23, N28, N43 and N52.

5

18. Polypeptide according to claim 17, comprising at least one of the following mutations: N3A, N6A, N6D, N11S, N23T, N28A and N43E.

10

19. Polypeptide, which constitutes a fragment of a polypeptide according to any preceding claim, which fragment retains binding affinity for HER2.

15

20. Polypeptide according to any preceding claim, which comprises additional amino acid residues at either terminal.

20

21. Polypeptide according to claim 20, in which the additional amino acid residues comprise a cysteine residue at the N- or C-terminal of the polypeptide.

25

22. Polypeptide according to any one of claims 20-21, in which the additional amino acid residues comprise a tag, preferably chosen from a hexahistidinyl tag, a myc tag and a flag tag.

30

23. Polypeptide according to any one of claims 20-21, in which the additional amino acid residues comprise at least one functional polypeptide domain, so that the polypeptide is a fusion polypeptide between a first moiety, consisting of the polypeptide according to any one of claims 1-19, and at least one second and optionally further moiety or moieties.

35

24. Polypeptide according to claim 23, in which the second moiety consists of one or more polypeptide(s) according to any one of claims 1-19, making the polypeptide

a multimer of HER2 binding polypeptides according to any one of claims 1-19, the sequences of which may be the same or different.

- 5 25. Polypeptide according to claim 23, in which the second moiety comprises at least one polypeptide domain capable of binding to a target molecule other than HER2.
- 10 26. Polypeptide according to claim 25, in which the second moiety comprises at least one polypeptide domain capable of binding to human serum albumin.
- 15 27. Polypeptide according to claim 26, in which the at least one polypeptide domain capable of binding to human serum albumin is the albumin binding domain of streptococcal protein G.
- 20 28. Polypeptide according claim 25, in which the second moiety comprises a polypeptide which is related to a domain of staphylococcal protein A (SPA) in that the sequence of the polypeptide corresponds to the sequence of the SPA domain having from 1 to about 20 substitution mutations.
- 25 29. Polypeptide according claim 28, in which the sequence of the second moiety polypeptide corresponds to the sequence of SPA protein Z, as set forth in SEQ ID NO:1, having from 1 to about 20 substitution mutations.
- 30 30. Polypeptide according to claim 23, in which the second moiety is capable of enzymatic action.
- 35 31. Polypeptide according to claim 23, in which the second moiety is capable of fluorescent action.

32. Polypeptide according to claim 23, in which the second moiety is a phage coat protein or a fragment thereof.

5 33. Polypeptide according to any preceding claim,
which comprises a label group.

34. Polypeptide according to claim 33, in which the label group is chosen from fluorescent labels, biotin and radioactive labels.

35. Polypeptide according to any one of the preceding claims, conjugated to a substance having an activity against cells overexpressing HER2.

36. Polypeptide according to claim 35, in which said substance having an activity against cells overexpressing HER2 is chosen from cytotoxic agents, radioactive agents, enzymes for ADEPT applications, cytokines and procoagulant factors.

37. Nucleic acid molecule comprising a sequence encoding a polypeptide according to any one of claims 1-32.

25 38. Expression vector comprising the nucleic acid
molecule according to claim 37.

39. Host cell comprising the expression vector according to claim 38.

40. Use of a polypeptide according to any one of claims 1-36 as a medicament.

41. Use of a polypeptide according to any one of
35 claims 1-36 in the preparation of a medicament for the
treatment of at least one form of cancer characterized by
overexpression of HER2.

42. Method of treatment of at least one form of cancer characterized by overexpression of HER2, which method comprises administering to a subject in need of such
5 treatment a therapeutically effective amount of a composition, which comprises a polypeptide according to any one of claims 1-36 as an active substance.

43. Use of a polypeptide according to any one of
10 claims 1-36 conjugated to a substance with anti-cancer activity for delivery of said substance to cells that overexpress HER2.

44. Method of directing a substance having an anti-
15 cancer activity to cells overexpressing HER2 *in vivo*, which method comprises administering a conjugate of said substance and a polypeptide according to any one of claims 1-36 to a subject.

45. Use of a polypeptide according to any one of
20 claims 1-36 for the detection of HER2 in a sample.

46. Method of detection of HER2 in a sample, in
25 which method a polypeptide according to any one of claims 1-36 is used.

47. Method according to claim 46, comprising the
steps: (i) providing a sample to be tested, (ii) applying
30 a polypeptide according to any one of claims 1-36 to the sample under conditions such that binding of the polypeptide to any HER2 present in the sample is enabled, (iii) removing non-bound polypeptide, and (iv) detecting bound polypeptide.

48. Method according to claim 47, in which the sam-
35 ple is a biological fluid sample, preferably a human blood plasma sample.

49. Method according to claim 47, in which the sample is a tissue sample, preferably a human tissue sample, more preferably a biopsy sample from a human suffering from cancer.

50. Kit for diagnosis of HER2 overexpression in a tissue sample, which kit comprises a polypeptide according to any one of claims 1-36 fused to a reporter enzyme, reagents for detection of activity of said reporter enzyme, and positive and negative control tissue slides.

51. Kit for *in vivo* diagnosis of HER2 overexpression, which kit comprises a polypeptide according to any one of claims 1-36 labeled with a chelator, a diagnostic radioactive isotope, and reagents for the analysis of the incorporation efficiency.

52. Kit for performing the method of claim 44, which kit comprises a polypeptide according to any one of claims 1-36 labeled with a chelator, a therapeutic radioactive isotope, and reagents for the analysis of the incorporation efficiency.

9. FEB2004 15:58

AWAPATENT_+4684409550
AWAPATENT

NR. 1306 S. 24

ink 1.7

8 9

Proprietary

1

SEQUENCE LISTING

<110> Affibody AB

<120> NEW POLYPEPTIDE

<130> 21012330

<160> 5

<170> PatentIn version 3.1

<210> 1

<211> 58

<212> PRT

<213> Synthetic polypeptide

<400> 1

Val Asp Asn Lys Phe Asn Lys Glu Gln Gln Asn Ala Phe Tyr Glu Ile
1 5 10 15

Leu His Leu Pro Asn Leu Asn Glu Glu Gln Arg Asn Ala Phe Ile Gln
20 25 30

Ser Leu Lys Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala
35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys
50 55

<210> 2

<211> 58

AWAPATENT_+4684409550
AWAPATENT

Est. 1911

03

הדפוס: א. גולן

2

<213> Synthetic polypeptide

<400> 2

Val Asp Asn Lys Phe Asn Lys Glu Leu Arg Gln Ala Tyr Trp Glu Ile
1 5 10 15

Gln Ala Leu Pro Asn Leu Asn Trp Thr Gln Ser Arg Ala Phe Ile Arg
20 25 30

Ser Leu Tyr Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala
35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys
50 55

<210> 3

<211> 58

<212> PRT

<213> Synthetic polypeptide

<400> 3

Val Asp Asn Lys Phe Asn Lys Glu Pro Lys Thr Ala Tyr Trp Glu Ile
1 5 10 15

Val Lys Leu Pro Asn Leu Asn Pro Glu Gln Arg Arg Ala Phe Ile Arg
20 25 30

Ser Leu Tyr Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala
35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys
50 55

<210> 4

<211> 58

9. FEB2004 15:58

AWAPATENT_+4684409550
AWAPATENT

NR. 1306 S. 56

Ink. t. Patent- och reg.verket

2004-02-09

3

<212> PRT

<213> Synthetic polypeptide

<400> 4

Val Asp Asn Lys Phe Asn Lys Glu Pro Arg Glu Ala Tyr Trp Glu Ile
1 5 10 15

Gln Arg Leu Pro Asn Leu Asn Asn Lys Gln Lys Ala Ala Phe Ile Arg
20 25 30

Ser Leu Tyr Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala
35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys
50 55

<210> 5

<211> 58

<212> PRT

<213> Synthetic polypeptide

<400> 5

Val Asp Asn Lys Phe Asn Lys Glu Trp Val Gln Ala Gly Ser Glu Ile
1 5 10 15

Tyr Asn Leu Pro Asn Leu Asn Arg Ala Gln Met Arg Ala Phe Ile Arg
20 25 30

Ser Leu Ser Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala
35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys
50 55

ABSTRACT

A polypeptide is provided, which has a binding affinity for HER2 and which is related to a domain of staphylococcal protein A (SPA) in that the sequence of the polypeptide corresponds to the sequence of the SPA domain having from 1 to about 20 substitution mutations. Nucleic acid encoding the polypeptide, as well as expression vector and host cell for expressing the nucleic acid, are also provided.

Also provided is the use of such a polypeptide as a medicament, and as a targeting agent for directing substances conjugated thereto to cells overexpressing HER2.

Methods, and kits for performing the methods, are also provided, which methods and kits rely on the binding of the polypeptide to HER2.

4
1
6
0
0
5
0

1/18

PL
U S
Patent Office

Polypeptide	Amino acid sequence	SEQ ID NO:
Z _{HER2}	VDNKENKEQQ NAFYEIILHP NLNNEEQRNAF IQSLKODPSQ SANLLAEAKK LNDQAQPK	1
Z _{HER2} A	VDNKENKELR QAYWEIQALP NLNWTQSRF IRSLYDDPSQ SANLLAEAKK LNDQAQPK	2
Z _{HER2} B	VDNKENKEPK TAYWEIVKLP NLNPEQRRF IRSLYDDPSQ SANLLAEAKK LNDQAQPK	3
Z _{HER2} C	VDNKENKEPR EAYWEIQRLP NLNKKQKAF IRSLYDDPSQ SANLLAEAKK LNDQAQPK	4
Z _{HER2} D	VDNKENKEWV QAGSEIYNLP NLNRAQWRF IRSLSDDPSQ SANLLAEAKK LNDQAQPK	5

FIGURE 1

9. FEB2004 15:59

AWAPATENT_+4684409550
AWAPATENT

NR. 1306 S. 20

Pat. Patent och reg. verkst

2002-09

Patent och reg. verkst

2/18



FIGURE 2

040003754

9. FEB2004 15:59

AWAPATENT_+468440955(A
AWAPATENT

NR. 1306 S. 59

3/18

Ink. t. Patent- och reg.verket

5000-02-09

12.000.000.000.000




FIGURE 3

4/18




FIGURE 4

5/18

Inkl. t. Patent- och reg. verkst

100-02-09

100-02-09




FIGURE 5

04.00.2004

9. FEB2004 15:59

AWAPATENT_+4684409550
AWAPATENT

NK. 1300 0. 02

Ink. t. Patent- och registeret

2004-02-09

Patent- och registeret

6/18




FIGURE 6

7/18

lek + Patent- och reg.verket

2004-02-09

Patent- och reg.verket




FIGURE 7

8/18

Ink. t. Patent- och förvaltnings

2004-02-09

Handläggare: L. J. J.




FIGURE 8A

01.003.735.4

9/18




FIGURE 8B

10/18




FIGURE 9

36000754

11/18

Inkl. t. Patent- och praxis

2004-02-09

Neurologi




FIGURE 10

12/18

Ink t Patent och nyhet

2001 02- 0 9

11-11-11

Blocked vs non-blocked




FIGURE 11

13/18

Ink. t. Patent- och registreringsverket

2004-02-09

13/18

Specific vs unspecific affibody




FIGURE 12

14/18

14/18

14/18

Biodistribution, combined data




FIGURE 13

15/18

Biodistribution at 8 h ip






FIGURE 14

16/18

lek 1. Patient- och n.g.verket

704-62-03

11. 11. 1941



17/18

Ex. 1. Proof- by induction

CONFIDENTIAL

הענין הזה ..





FIGURE 16

18/18

Int. J. Cancer 107:100-104 (2001)

© 2001 Blackwell Science Ltd

J. Natl. Cancer Inst. 93:100-104 (2001)



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.